GH Stock Forecast & Price Target

Guardant Health is viewed as a dominant liquid-biopsy leader with durable franchise breadth across Guardant360, Reveal, and Shield, supported by strong clinical adoption, a ~20,000-patient ECLIPSE study, and Q1’26 revenue of $302M, up 48% year over year. The bullish case is strengthened by faster-than-expected payor and guideline traction, including UnitedHealthcare coverage for Shield effective August 1, 2026, NCCN and ACS inclusion, and FDA approval of G360CDx, all of which should expand volumes and improve ASPs across the portfolio. Financially, Guardant raised its 2026 revenue guide to $1.30-1.32B, held $1.2B of cash, and is positioned for operating leverage as reimbursement, pricing, and test frequency continue to scale.

Guardant Health is challenged by a competitive landscape across precision oncology, MRD, and early detection, where rivals in tissue and blood testing could slow Guardant360 growth and limit Reveal Ultra’s traction in a crowded MRD market. Although Q1'26 Shield CRC revenue of about $42M and roughly 44k volumes were strong, the company’s reliance on Medicare pricing at $1,495 per test through YE'27 may not be durable as commercial reach expands and rev/test normalizes. Cash burn above $200M in each of the past two years, with acceleration in the most recent quarter and breakeven not targeted until Q4 2027, heightens balance-sheet risk if adoption, reimbursement, or USPSTF support for blood-based screening underdelivers.